Affinity Chromatography Resins For Complex Antibody Purification

The biopharmaceutical landscape is shifting from traditional monoclonal antibodies toward complex modalities like bispecifics, multispecifics, and fragments. These next-generation therapies offer enhanced efficacy and precision, transforming medicine and tackling complex diseases. However, they also introduce significant manufacturing hurdles, particularly during affinity purification. Modern purification strategies now utilize specialized resins to overcome these barriers.

For example, standard Protein A approaches often struggle with these molecules due to the absence of an Fc region or the high risk of aggregation caused by the low pH levels required for elution. By targeting the CH1 domain instead of the Fc region, developers can effectively purify antibody fragments and multispecifics that were previously difficult to isolate.

Understanding these advanced resin technologies is essential for improving manufacturing efficiency and ensuring product consistency in an increasingly competitive market. Download the eBook below to learn more about the latest strategies and technologies for complete antibody purification.